Intestinal lipid absorption and lipoprotein formation : Current Opinion in Lipidology

Secondary Logo

Journal Logo

LIPID METABOLISM: Edited by Ernst J. Schaefer

Intestinal lipid absorption and lipoprotein formation

Hussain, M. Mahmooda,b,c

Author Information
Current Opinion in Lipidology 25(3):p 200-206, June 2014. | DOI: 10.1097/MOL.0000000000000084

Abstract

Purpose of review 

To summarize the evidence for the presence of two lipid absorption pathways and their regulation.

Recent findings 

Lipid absorption involves hydrolysis of dietary fat in the lumen of the intestine, followed by the uptake of hydrolyzed products by enterocytes. Lipids are resynthesized in the endoplasmic reticulum and are either secreted with chylomicrons and HDLs or stored as cytoplasmic lipid droplets. Lipids in the droplets are hydrolyzed and are secreted at a later time. Secretion of lipids by the chylomicron and HDL pathways are dependent on microsomal triglyceride transfer protein (MTP) and ATP-binding cassette family A protein 1, respectively, and are regulated independently. Gene-ablation studies showed that MTP function and chylomicron assembly is essential for the absorption of triglycerides. Ablation of MTP abolishes triglyceride absorption and results in massive triglyceride accumulation in enterocytes. Although the majority of phospholipid, cholesterol, and vitamin E are absorbed through the chylomicron pathway, a significant amount of these lipids are also absorbed via the HDL pathway. Chylomicron assembly and secretion is increased by the enhanced availability of fatty acids, whereas the HDL pathway is upregulated by liver X receptor agonists.

Summary 

Triglycerides are exclusively transported with chylomicrons and this process is critically dependent on MTP. In addition to chylomicrons, absorption of phospholipids, free cholesterol, retinol, and vitamin E also involves HDLs. These two pathways are complementary and are regulated independently. They may be targeted to lower lipid absorption in order to control hyperlipidemia, obesity, metabolic syndrome, steatosis, insulin resistance, atherosclerosis, and other disorders.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

You can read the full text of this article if you:

Access through Ovid